Neovacs SA, a developer of immunotherapies for autoimmune diseases, has named Miguel Sieler as its chief executive officer, replacing Guy-Charles Fanneau De La Horie. Mr Sieler was formerly chairman and chief executive of Bayer France. He is also a member of the board of Nexity SA and chairman of Wittycell, a French biotechnology company developing vaccine adjuvants. Mr Sieler holds a Master in Law degree from the University of Tübingen, and graduated from the Institut d’Études Politiques de Paris in France.
Neovacs announced the appointment on 18 October 2013.
Copyright 2013 Evernow Publishing Ltd